Abstract: Ｏｂｊｅｃｔｉｖｅ：The aim of this study was to clarify the efficacy and safety of double filtration plasmapheresis (DFPP) in refractory hyperlipidemia.
Ｍｅｔｈｏｄｏｌｏｇｙ：Patients who received DFPP due to refractory hyperlipidemia from January 2016 to June 2020 in Center for Kidney Disease, 2nd Affiliated Hospital of Nanjing Medical University were analyzed retrospectively.The efficacy and safety of DFPP were evaluated.Serum triglycerides(TG), total cholesterol(TC), platelets, fibrinogen, immunoglobulin and serum albumin were monitored.
Ｒｅｓｕｌｔｓ：11 patients with refractory hyperlipidemia (male:femal 9: 2, average age of 440±30 years) received DFPP for 25 sessions.Major diseases of them were acute pancreatitis (5 cases) (455％), type 2 diabetes (3 cases) (273％), membrane nephropathy／familial hyperlipidemia／pregnancy status(1 case for each) (91％).After single DFPP, TG dropped from 285±52 mmol／L to 96±17 mmol／L(reduction rate 612％ ± 162％).TC and lowdensity lipoprotein decreased rapidly with the reduction rates 508％ ± 152％ and 445％±218％, respectively.There were no significant changes of serum albumin, IgG or platelet after DFPP.There was no adverse reaction during DFPP in this study.
Ｃｏｎｃｌｕｓｉｏｎ：The preliminary study proved the efficacy and safety of DFPP in refractory hyperlipidemia.Howerever, the application of DFPP in refractory hyperlipidemia still needs further studies.

Key words: hyperlipidemia, double filtration plasmapheresis, therapy